Advocacy intelligence hub — real-time data for patient organizations
Rezzayo: FDA approved
in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis
Abelcet: FDA approved
Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Abelcet
Liposome Company, Inc.
REZZAYO
Melinta
Abelcet
(Amphotericin B lipid complex)Orphan drugLiposome Company, Inc.
Browse all Transient predisposition to invasive pyogenic bacterial infection news →
View all Transient predisposition to invasive pyogenic bacterial infection specialists →